Replikun Biotech is developing products for exciting, growing markets: preventative vaccines for intractable infections and therapeutic vaccines against infectious diseases and cancer.

Replikun's proprietary technology, the Kunjin Replicon, builds vaccines that fight against immune evasion - the sophisticated processes by which viruses, bacteria and cancer cells disguise their presence and hide from the immune system. 

The Kunjin replicon has the unusual property of being persistent and self-replicating.  This mix of properties allows a new style of vaccination based on persistent exposure to antigen in the relative absence of severe, anti-viral “danger signals”.